As immuno-anticancer drugs can be used in early lung cancer, the prognosis of patients is improving. Unlike before, when chemotherapy and concurrent chemoradiation were all, it is evaluated that the number of cases of 'complete pathological remission' has increased. Opdivo was approved by the Ministry of Food and Drug Safety in October of last year for adjuvant therapy before non-small cell lung cancer surgery. This is the first case in which immuno-oncology drugs have advanced into adjuvant therapy before surgery. Specifically, Opdivo can be used along with chemotherapy in non-small cell lung cancer patients with tumors larger than 4 cm or with positive lymph nodes. The treatment proceeds by using 3 cycles of Opdivo + c